


PRODUCT INFORMATION



Prazosin (hydrochloride)

Item No. 15023

CAS Registry No.: 19237-84-4
Formal Name: [4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl]-2-furanyl-methanone, monohydrochloride
Synonyms: CP 12,299-1, NSC 292810
MF: C₁₉H₂₁N₅O₄ • HCl
FW: 419.9
Purity: ≥98%
UV/Vis.: λ_{max}: 214, 247, 330, 342 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Prazosin (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the prazosin (hydrochloride) in the solvent of choice, which should be purged with an inert gas. Prazosin (hydrochloride) is soluble in the organic solvent DMSO at a concentration of approximately 0.1 mg/ml.

Description

Prazosin is an antagonist of α_1 -adrenergic receptors (α_1 -ARs).^{1,2} It selectively binds to α_1 -ARs with K_i values of 0.2, 0.25, and 0.32 nM for the human recombinant α_{1A} -, α_{1B} -, and α_{1D} -ARs, respectively, over α_2 -ARs (K_i s = 340 and 3.7 nM in α_{2A} -AR-expressing HT-29 cells and α_{2B} -AR-expressing NG108 cells, respectively).^{3,4} It also binds to melatonin receptor 3 (MT₃) in hamster brain membranes (IC₅₀ = 7.8 nM).⁵ Prazosin inhibits peripheral and central postsynaptic α_1 -ARs with IC₅₀ values of 0.2 and 1.7 nM in isolated dog aorta and rat brain, respectively.¹ It decreases diastolic blood pressure in normal, renal hypertensive, and spontaneously hypertensive rats when administered at a dose of 1 mg/kg.⁶ Prazosin (1.5 mg/kg) increases the number of entries and percentage of time spent in the open arms of the elevated plus maze, indicating anxiolytic-like activity, in alcohol-consuming rats and also reduces alcohol intake and alcohol-seeking behavior in alcohol-preferring rats.^{7,8}

References

1. Nagatomo, T., Tsuchihashi, H., Sasaki, S., et al. *Japan J. Pharmacol.* **37(2)**, 181-187 (1985).
2. Kristek, F. and Koprdoва, R. *J. Physiol. Pharmacol.* **62(3)**, 295-301 (2011).
3. Leiker, A.J., DeGraff, W., Choudhuri, R., et al. *Clin. Cancer Res.* **21(12)**, 2792-2801 (2015).
4. Bylund, D.B., and Ray-Prenger, C. *J. Pharmacol. Exp. Ther.* **251(2)**, 640-644 (1989).
5. Paul, P., Lahaye, C., Delagrangé, P., et al. *J. Pharmacol. Exp. Ther.* **290(1)**, 334-340 (1999).
6. Fernandes, M., Smith, I.S., Weder, A., et al. *Clin. Sci. Mol. Med. Suppl.* **48**, 181s-184s (1975).
7. Verplaetse, T.L., Rasmussen, D.D., Froehlich, J.C., et al. *Alcohol Clin. Exp. Res.* **36(5)**, 881-886 (2012).
8. Skelly, M.J. and Weiner, J.L. *Brain Behav.* **4(4)**, 468-483 (2014).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/01/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM